Navigation Links
Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
Date:8/4/2008

WEIFANG, Shandong, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has retained Grayling Global to lead a strategic communications program ("the IR program") to shareholders, the investment community and financial media.

As the investor relations counsel for Shengtai Pharmaceutical, Grayling Global will help raise the investment community's awareness of the Company's performance through timely corporate updates, direct communications with fund managers, financial media placements and investor conference presentations. "We are pleased to have a global IR network and its senior counselors with long standing healthcare and industrial track records to help us raise our financial profile and ensure the full understanding of our business model and exciting growth prospects," said Mr. Qingtai Liu, Chief Executive Officer of Shengtai Pharmaceutical. "We need to increase our visibility and expand our relationships with U.S. investors. As we are becoming a bigger company and planning to move onto main exchange, we believe Grayling Global is best suited to guide this investor relations process."

Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), is headquartered in London, with offices in New York, Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Hong Kong, Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm has over 200 consultants, focusing on first-class delivery in public affairs, public relations, investor relations and events management.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Shengtai Pharmaceutical, Inc.

Ms. Melody Shi

Chief Financial Officer

Tel: +1-949-468-7078

Email: shengtaicfo@hotmail.com

Grayling Global

Eddie Cheung

Investor Relations

Tel: +1-646-284-9414

Email: echeung@hfgcg.com


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shengtai Pharmaceutical, Inc. Appoints New CFO
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
3. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
4. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
7. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
10. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
11. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeqâ„¢ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
(Date:12/8/2016)... , Dec. 8, 2016 Savannah ... remediation technologies and selected NewTechBio,s NT-MAX Lake ... microbial based beneficial bacteria, in conjunction with Hexa ... correct deficiencies with National Pollutant Discharge Elimination System ... has experienced a steady history of elevated pH ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
Breaking Biology News(10 mins):